Search

Your search keyword '"Casey Sm"' showing total 2 results
Start Over Author "Casey Sm" Publisher international institute of anticancer research
2 results on '"Casey Sm"'

1. RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance.

Author

Slate DL, Bruno NA, Casey SM, Zutshi N, Garvin LJ, Wu H, and Pfister JR

Subjects
ATP Binding Cassette Transporter, Subfamily B, Member 1 drug effects, Animals, Cell Division drug effects, Cell Line, Cricetinae, Cricetulus, Dibenzocycloheptenes therapeutic use, Doxorubicin metabolism, Doxorubicin toxicity, Drug Synergism, Etoposide toxicity, Mice, Mice, Nude, Paclitaxel toxicity, Quinolines therapeutic use, Sarcoma drug therapy, Transplantation, Heterologous, Vincristine therapeutic use, Vincristine toxicity, ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Antineoplastic Agents toxicity, Dibenzocycloheptenes pharmacology, Drug Resistance, Multiple physiology, Leukemia P388 drug therapy, Quinolines pharmacology
Abstract

A novel multidrug resistance modulator, RS-33295-198, circumvented drug resistance in human, mouse, and Chinese hamster cell lines overexpressing P-glycoprotein. It enhanced the antiproliferative activity of doxorubicin, vincristine, etoposide, and paclitaxel and increased doxorubicin retention in multidrug-resistant hamster CHRC5 cells. RS-33295-198 modulated doxorubicin resistance in a murine P388/ADR leukemia model when administered ip via continuous minipump delivery, ip by bolus injection, and orally; it also improved the efficacy of vincristine toward P388/VCR leukemia when given ip or po. RS-33295-198 showed weak activity in enhancing doxorubicin efficacy against a multidrug-resistant human sarcoma xenograft.

Published
1995

2. Modulation of doxorubicin efficacy in P388 leukemia following co-administration of verapamil in mini-osmotic pumps.

Author

Slate DL, Fraser-Smith EB, Rosete JD, Freitas VR, Kim YN, and Casey SM

Subjects
Animals, Doxorubicin administration & dosage, Drug Resistance, Drug Therapy, Combination, Female, Infusions, Parenteral, Injections, Intraperitoneal, Mice, Mice, Inbred Strains, Verapamil administration & dosage, Doxorubicin therapeutic use, Leukemia P388 drug therapy, Verapamil therapeutic use
Abstract

Co-administration of doxorubicin and verapamil in Alzet mini-osmotic pumps increased the survival of B6D2F1 mice bearing the multidrug-resistant P388/ADR leukemia. A range of doxorubicin and verapamil combinations was studied to define dose-dependent efficacy and toxicity. High doses of doxorubicin (10 mg/kg/day) and verapamil (150 mg/kg/day) could be administered alone without any effect on survival. However, combining high doses of these two agents resulted in host toxicity. Doxorubicin doses of 1 to 10 mg/kg/day in combination with verapamil at 25-100 mg/kg/day were found to improve survival compared with either agent alone. Combination therapy also improved the survival of mice bearing the drug-sensitive P388/0 leukemia when compared to anthracycline treatment alone. The efficacy of the mini-osmotic pump delivery protocol was compared with other regimens delivering the same total cumulative dose of doxorubicin via repeated i.p. injections.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results